Product Description
Rose Bengal Photodynamic Antimicrobial Therapy for Patients With Progressive Infectious Keratitis. RB-PDAT can be considered as an adjunct therapy for cases of severe, progressive infectious keratitis before performing a therapeutic keratoplasty. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/31493402/)
Mechanisms of Action: CRAC Stimulant
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Subcutaneous, Topical
FDA Designation: *
Approval Status: Approved
Approved Countries: Canada | Ireland | New Zealand | Taiwan | United Kingdom
Approved Indications: None
Known Adverse Events: None
Company: Provectus
Company Location: Western America
Company CEO: Bruce Horowitz
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Tobacco Use Disorder|Stomatitis, Denture|Acanthamoeba Keratitis|Keratitis
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
ChiCTR2200066207 |
ChiCTR2200066207 | N/A |
Not yet recruiting |
Pterygium |
2024-12-31 |
|||
NCT03031899 |
NCT03031899 | N/A |
Completed |
Lichen Planus, Oral|Anus Cancer|Oral Leukoplakia |
2016-03-01 |
2019-03-21 |
Treatments |
|
NCT06271772 |
REAGIR II | P3 |
Active, not recruiting |
Keratitis |
2026-06-30 |
2025-12-19 |
Primary Completion Date|Primary Endpoints|Treatments|Trial Status |
|
NCT05110001 |
REAGIR | P3 |
Completed |
Acanthamoeba Keratitis |
2024-12-14 |
2025-07-08 |
Primary Endpoints |
|
NCT04837664 |
KingSaudUni | P3 |
Unknown status |
Tobacco Use Disorder|Stomatitis, Denture |
2020-12-12 |
2023-04-04 |
Primary Endpoints|Treatments|Trial Status |